靶向α治疗:新兴抗癌药物类别综述
本文综述靶向α治疗(TAT)的放射生物学原理与临床进展,指出α粒子短射程高能量可致复杂双链DNA断裂并局限细胞毒作用于肿瘤及微环境;镭223二氯化物为首个获批用于伴骨转移的转移性去势抵抗性前列腺癌(mCRPC)的TAT,基于总生存获益,多种TAT正在多瘤种临床试验中探索。
要点
- α粒子短射程高能量致复杂双链DNA断裂,细胞毒作用局限于肿瘤及微环境。
- 镭223二氯化物是首个获批的TAT,用于伴骨转移的mCRPC且具总生存获益。
- 多种TAT正在多瘤种临床试验中探索,可能绕过获得性耐药机制。
核心结论
- 靶向α治疗是新兴治疗策略,可能绕过部分肿瘤的获得性耐药机制。
- 镭223的临床成功已验证TAT概念,未来研究可能为多瘤种提供新选择。
研究设计与样本
- 本文为综述,汇总靶向α治疗的放射生物学原理与临床研究进展。
主要发现
- α粒子高能量短射程发射导致复杂双链DNA断裂并引起细胞死亡。
- 尚未有α粒子耐药机制被报道或科学确立。
- α粒子短射程将细胞毒作用局限于癌性病灶及周围肿瘤微环境。
- 与β发射相比,α粒子放射生物学效能更高,诱导细胞死亡所需粒子径迹更少。
- 临床有效α同位素宜具短半衰期,以限制长期辐射暴露并便于生产制备与给药。
关键数值与推荐
- 镭223二氯化物为首个同类、市售靶向α治疗,获批用于伴骨转移的mCRPC患者。
- 镭223在mCRPC患者中已确立总生存获益。
临床怎么用
- 镭223二氯化物可用于伴骨转移的mCRPC患者,基于其总生存获益。
- 其他TAT在多瘤种临床试验中探索,临床决策需关注研究进展。
局限性
- 原文未报告具体研究样本量、疗效数值、置信区间或P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types. OBSERVATIONS: Theoretically, the high-energy emission of short-range alpha particles causes complex double-stranded DNA breaks, eliciting cell death. No known resistance mechanism to alpha particles has been reported or scientifically established. The short-range emission of alpha particle radiation confines its cytotoxic effect to cancerous lesions and the surrounding tumor microenvironment while limiting toxic effects to noncancerous tissues. The high level of radiobiological effectiveness of alpha particles, in comparison with beta emissions, requires fewer particle tracks to induce cell death. Clinically effective alpha particle-emitting isotopes for cancer therapy should have a short half-life, which will limit long-term radiation exposure and allow for the production, preparation, and administration of these isotopes for clinical use and application. Radium 223 dichloride is the first-in-class, commercially available targeted alpha therapy approved for the treatment of patients with metastatic castration-resistant prostate cancer with bone metastases. Given the established overall survival benefit conferred by radium 223 for patients with metastatic castration-resistant prostate cancer, several other targeted alpha therapies are being investigated in clinical trials across many tumor types. CONCLUSIONS AND RELEVANCE: Targeted alpha therapy represents an emerging treatment approach and provides for the possibility to bypass mechanisms of acquired resistance in selected tumors. In addition, developing novel radionuclide conjugation strategies may overcome targeting limitations. So far, the clinical success of radium 223 has demonstrated the proof of concept for targeted alpha therapy, and future studies may lead to additional treatment options for many cancer types.
引用
- Parker C, Lewington V, Shore N, et al. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncol. 2018. PMID: 30326033. doi:10.1001/jamaoncol.2018.4044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。